Sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs as a potential approach for advanced hepatocellular carcinoma with portal vein tumor thrombus: a prospective study
Shang Gao, Yanqin Hu, Yinbiao Cao, Weizheng Liu, Hongxiang Jiang, Tong Jiang, Haowen Tang, Shichun Lu · 2026
Read Sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs as a potential approach for advanced hepatocellular carcinoma with portal vein tumor thrombus: a prospective study by Shang Gao, Yanqin Hu, Yinbiao Cao, Weizheng Liu, Hongxiang Jiang, Tong Jiang, Haowen Tang, Shichun Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350586.txt.
Description
Shang Gao and co-authors studied prospectively in 2026 sequential surgery after conversion therapy for advanced liver cancer with portal vein tumour thrombus, a group facing very poor outlook. Immune therapy plus targeted therapy can at times shrink tumours enough to make surgery possible. Yet whether this sequence yields lasting survival gain was unclear.
Seventy-six patients with hepatocellular carcinoma and portal vein thrombus got programmed death-1 blockers plus tyrosine kinase blockers, followed by surgery when conversion worked. Long-term efficacy and safety were tracked. The prospective design tests a plan that turns an inoperable diagnosis into a possibly curative path, giving hope for patients whose tumours invade the main portal vein.
Catalog record
| CREATOR | Shang Gao, Yanqin Hu, Yinbiao Cao, Weizheng Liu, Hongxiang Jiang, Tong Jiang, Haowen Tang, Shichun Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |